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Abstract
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, which is closely related to hepatitis C and cirrhosis. The
molecular mechanisms underlying the hepatocarcinogenesis induced by HCV infection remain clarified from a standpoint of
systems biology. By integrating data from protein-protein interactions, transcriptional regulation, and disease related
microarray analysis, we carried out a dynamic biological network analysis on the progression of HCV induced
hepatocarcinogenesis, and systematically explored the potentially disease-related mechanisms through a network view.
The dysfunctional interactions among proteins and deregulatory relationships between transcription factors and their target
genes could be causes for the occurrence and progression of this disease. The six pathologically defined disease stages in
the development and progression of HCC after HCV infection were included in this study. We constructed disease-related
biological networks for each disease stage, and identified progression-related sub-networks that potentially play roles in the
developmental stage of the corresponding disease and participate in the later stage of cancer progression. In addition, we
identified novel risk factors related to HCC based on the analysis of the progression-related sub-networks. The dynamic
characteristics of the network reflect important features of the disease development and progression, which provide
important information for us to further explore underlying mechanisms of the disease.
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Introduction
Hepatocellular carcinoma (HCC) is a major health problem
worldwide. It is the sixth most common neoplasm in the world
with more than half a million new cases annually [1], and the main
cause of death among cirrhotic patients [2]. Hepatocarcinogenesis
is a complex and multistep process, which is associated with many
risk factors [3]. Hepatitis B virus (HBV) and hepatitis C virus
(HCV) infections, excessive alcohol consumption and aflatoxin are
widely recognized as the four major etiological factors of HCC [4].
Chronic infection with hepatitis B virus is the predominant risk
factor for HCC in Southeast Asia and Africa, while chronic
infection with hepatitis C virus is the predominant risk factor for
HCC in Western countries and Japan.
The risk of HCC in patients with chronic hepatitis C is the
highest and has been well studied in patients who have established
cirrhosis [5,6,7,8]. The incidence of HCC in patients with cirrhosis
is between 2%–8% per year as reported based on clinical studies.
A previous study showed that [9] 12,008 HCV-positive men
conferred a 20-fold increased risk of HCC compared to those
HCV-negative subjects. However, the presence or absence of
cirrhosis was not evaluated. It was reported that HCV-infected
individuals without cirrhosis had a much lower risk of developing
HCC [10]. Although previous clinically-based studies revealed
close relationships among hepatitis C, cirrhosis and HCC, the
underlying molecular mechanism of these phenomena remained
unclear.
As the center for the diversified metabolisms and detoxification,
liver plays various functions through different parenchymal cell
types. Each type of cell is composed of thousands of different types
of molecules. A discrete biological function can only rarely be
attributed to an individual molecule. In contrast, most biological
functions arise from interactions among many components.
Usually, ‘modules’ are used to describe this kind of biological
organization. Modules are composed of different types of
molecules. They have discrete functions that arise from interac-
tions among their components (proteins, DNA, RNA and small
molecules), but these functions cannot easily be predicted by
studying the properties of the isolated components [11].
Transcriptional regulatory interaction and protein-protein inter-
action are two of the most important interactions among these
components. Transcriptional regulation is the process in which
gene-encoded transcription factors regulate the transcription of
other genes. The assembly of regulatory interactions linking
transcription factors to their target genes in an organism can be
viewed as a directed graph, in which the nodes represent the
regulators and their targets, and the regulatory interactions are the
edges. Protein-protein interactions (PPIs) are crucial for all
biological processes [12]. Previous study on protein–protein
interaction networks in liver cancer detected many interactions
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glycoproteins, suggesting that a ‘‘molecule groups’’ concept should
be introduced in the diagnosis and metastasis prediction of HCC
instead of analyzing a single, or a few proteins [13]. In all, because
the majority of gene products function together with other gene
products, biological processes should be considered as complex
networks of interconnected components. In other words, for any
biological process, one might consider a ‘modular approach’ in
which the behavior and function of the corresponding network are
studied as a whole, in addition to studying some of its components
individually [11].
Recently, the innovation of high throughput experimental
strategies makes it possible for biology to become holistic [14].
With the tremendous increase in human protein interaction data,
network approaches have already been employed to understand
molecular mechanisms of diseases [15], particularly to analyze
carcinogenesis and the genotype related to the cancer phenotype.
However, most efforts only focused on protein-protein interaction
network. Moreover, few of these efforts studied dynamic changes
of the network during the development and progression from pre-
HCC disease to HCC, which will facilitate us to understand the
molecular mechanisms of hepatocarcinogenesis.
Our hypothesis is that the dysfunctional genes/proteins and
interactions among them at each progression-related sub-network
are strongly related to the special disease pathogenic state, and
play a role in the disease progression. Networks related to each
stage of the disease can capture the pathogenic characteristics of
corresponding disease stages and reflect the role of those genes/
proteins in the development and progression of hepatocarcino-
genesis at the disease specific stage. Based on this hypothesis, we
have integrated multiple data at different levels, especially with
regard to biological pathways and interaction networks, and built a
hepatocellular carcinoma biological network database previously
[16]. The integrated network lays the foundation for our current
work. With the integration of protein-protein interactions data,
transcriptional regulatory interactions (TRIs) data and microarray
data covering hepatitis C, cirrhosis and Barcelona Clinic Liver
Cancer (BCLC) staging HCC, we carried out a dynamic biological
network analysis for the progression of HCV induced hepatocar-
cinogenesis.
Results
Biological network and interaction annotation
In our previous work, we have integrated a set of human
protein-protein interaction data and transcriptional regulatory
interaction data, which contains 37811 experimentally confirmed
protein-protein interactions and 9148 experimentally confirmed
transcriptional regulatory interactions [16]. These interactions
form a molecular biological network in humans. Gene Ontology is
Figure 1. Disease related biological networks. Edge color: red, PPI; green, TRI. Edge direction: undirected, PPI; directed, TRI, from transcriptional
factor to target gene. (A) Hepatitis related biological network; (B) cirrhosis related biological network; (C) BCLC stage 0 HCC related biological
network; (D) BCLC stage A HCC related biological network; (E) BCLC stage B HCC related biological network; (F) BCLC stage C HCC related biological
network.
doi:10.1371/journal.pone.0018516.g001
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However, the function of a module in a network is not only
determined by a group of individual molecules, but also the
functional association between them. Therefore, annotating the
function of these interactions in a biological network will facilitate
us to understand systemic functions in the biological network. A
transcription factor may achieve its function by regulating the
expression of target genes that implement the same function. In
this way, if a transcription factor and its target gene could be
mapped to a same function annotation, the TRI between them
may also participate in this function. Based on Gene Ontology
annotation data, which is supported by experimental evidence, we
annotated interactions of the human biological network. Finally,
21365 PPIs and 3587 TRIs were annotated by this method.
Disease-related biological network
Biological networks provide valuable information for under-
standing cellular function and biological processes. The dysfunc-
tion of some interactions causes many diseases, including cancers.
Therefore, studying the deregulated biological networks will help
us to understand molecular mechanisms of these diseases. First, we
identified DEGs (Differentially Expressed Genes) by bioinfor-
matics analysis of the microarray data that cover Hepatitis C,
Cirrhosis, and BCLC staging HCC. Then we mapped those DEGs
to protein-protein interactions data and transcriptional regulatory
interactions data integrated in HCCNet database [16], which was
a HCC network database previously established by our team. In
each disease stage, the PPI between DEGs-encoded proteins, and
the TRI between the DEG-encoded transcription factor and its
target gene in DEGs were regarded as deregulated. By integrating
these interactions, we constructed disease-related biological
networks that were deregulated in each disease stage (see details
in material and method).
Several classification systems are available for HCC. The
Barcelona Clinic Liver Cancer (BCLC) classification has emerged
during recent years as the standard classification that is used for
trial design and clinical management of patients with HCC
[18,19]. It divides HCC into five stages. Patients with end-stage
disease (stage D) have a reported median survival of only 3 months
[18]. Therefore, this stage is excluded in the following study. Six
disease stages in the development and progression of HCV
induced hepatocarcinogenesis are included in our study including
Hepatitis C, Cirrhosis, BCLC stage 0 HCC, BCLC stage A HCC,
BCLC stage B HCC, BCLC stage C HCC. We identified disease-
related biological networks for each disease stage with the process
described above (Figure 1). The deregulated biological network of
Figure 2. Sub networks identified in developing progression of HCV induced hepatocarcinogenesis. Edge color: red, PPI; green, TRI.
Edge direction: undirected, PPI; directed, TRI, from transcriptional factor to target gene. (A) sub networks that were deregulated initially from
hepatitis; (B) the ones that were deregulated initially from cirrhosis; (C) the ones that were deregulated initially form BCLC stage 0 HCC; (D) the ones
that were deregulated initially form BCLC stage A HCC; (E) the ones that were deregulated initially form BCLC stage B HCC; (F)the ones that were
deregulated initially form BCLC stage C HCC.
doi:10.1371/journal.pone.0018516.g002
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while the deregulated biological network of cirrhosis included 166
nodes and 197 edges. The deregulated biological network of
BCLC stage 0 HCC was composed of 883 nodes and 1545 edges.
Meanwhile, the deregulated biological network of BCLC stage A
HCC contained 734 nodes and 1057 edges. The deregulated
biological network of BCLC stage B HCC was generated with
1053 nodes and 1783 edges. The deregulated biological network of
BCLC stage C HCC was constructed by 1277 nodes and 2378
edges (Supplementary Data S1). In these networks, edges represent
PPIs or TRIs. Line in PPI is undirected when line in TRI is
directed. Nodes linked by the edge in PPI are proteins. The edge
in TRI goes from transcription factor to its target gene.
Dynamic deregulated biological network
Comparison among deregulated biological networks shows that
when the disease progression switches sequentially from hepatitis
C to BCLC stage C HCC, the deregulated biological network
changes correspondingly. The dynamic network implies the
potential molecular mechanism that underlies the development
and progression of the carcinogenesis. Some interactions were
deregulated consistently in different stages during the disease
development and progression. We hypothesize that these shared
interactions participate in the development and progression of the
carcinogenesis. For example, an interaction that was deregulated
in hepatitis C initially and remained dysfunctional in the following
cirrhosis and at all the stages of HCC may participate in the
hepatitis C infection, and the development and progression from
hepatitis C to BCLC stage C HCC.
Based on the above hypothesis, we made a comparison among
the six disease-related biological networks in the development and
progression. 42 interactions were deregulated initially from
hepatitis C to BCLC stage C HCC. 26 interactions were
deregulated initially from cirrhosis, which means that they were
not deregulated in hepatitis C but in cirrhosis, BCLC stage 0
HCC, BCLC stage A HCC, BCLC stage B HCC and BCLC stage
C HCC. Accordingly, 224 interactions showed deregulated only
from BCLC stage 0 HCC when 114 interactions were deregulated
initially from BCLC A HCC. Furthermore, 156 interactions were
indentified deregulated initially from BCLC B HCC and 1186
interactions were recognized as deregulated initially from BCLC C
HCC (Supplementary Data S2). By integrating interactions that
were deregulated initially from the same stage, progression-related
sub-networks, which contains fifty six sub-networks (node.=3),
were constructed (Figure 2).
Functional annotation of progression-related
sub-networks
In our hypothesis, genes and proteins in a progression-related
sub-network may function together in the progression of HCV
induced hepatocarcinogenesis. To better understand their func-
tions in the progression, especially the role of the sub-network in
the progression, we need to find out which function is significant
comparing to the whole human biological network. Gene
Ontology enrichment analysis is usually used to identify statisti-
cally significant functions of a group of genes. However, this
method treats those genes as individual components and ignores
their association, which is the base of a module. We have
annotated integrated human biological networks with Gene
Ontology data, which is supported by experimental evidence.
Based on hypergeometric distribution, we carried out a function
enrichment analysis between the progression-related sub-network
and the whole human biological network. Statistically significant
functions (p value,0.01) of the progression-related sub-networks,
which indicate the functional difference comparing to the whole
biological network, were identified through this analysis. In the
total number of fifty six sub-networks, twenty seven of them were
identified with statistically significant functions (Supplementary
Data S3). The genes and proteins in the progression-related sub-
network identified with statistically significant functions may work
together in the progression of HCV induced hepatocarcinogenesis.
Furthermore, the statistically significant functions of the
Table 1. Significant functions (P value,0.01) of the progression-related sub network deregulated initially from hepatitis C.
GO ID P value Name
GO:0050731 1.28E-03 positive regulation of peptidyl-tyrosine phosphorylation
GO:0004896 1.70E-04 cytokine receptor activity
GO:0030890 5.96E-04 positive regulation of B cell proliferation
GO:0001961 1.70E-04 positive regulation of cytokine-mediated signaling pathway
GO:0043518 5.11E-04 negative regulation of DNA damage response, signal transduction by p53 class mediator
GO:0008283 1.11E-03 cell proliferation
GO:0016021 1.96E-03 integral to membrane
GO:0001516 3.41E-04 prostaglandin biosynthetic process
GO:0002792 1.70E-04 negative regulation of peptide secretion
GO:0019955 3.41E-04 cytokine binding
GO:0001540 5.96E-04 beta-amyloid binding
GO:0007165 3.66E-03 signal transduction
GO:0048146 0.00127703 positive regulation of fibroblast proliferation
GO:0043066 0.004082191 negative regulation of apoptosis
GO:0005773 0.000170341 Vacuole
GO:0009986 0.005609786 cell surface
GO:0070374 0.000766365 positive regulation of ERK1 and ERK2 cascade
doi:10.1371/journal.pone.0018516.t001
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and proteins perform by synergistic action.
We offered these progression-related sub-networks and their
statistically significant functions in the supplementary materials.
In our hypothesis, the sub-network that is deregulated from
hepatitis C is considered a cirrhosis-HCC-risk sub-network.
The dysfunction of it could increase the risk of cirrhosis and
following HCC incidence of hepatitis C patients. Many
functions that related to cirrhosis and cancer are significantly
enriched in this sub-network, such as cell proliferation, positive
regulation of fibroblast proliferation, negative regulation of
apoptosis, etc. (Table 1). The sub-networks which are
deregulated from cirrhosis can be regarded as HCC-risk sub-
networks. The dysfunction of them could increase HCC
incidence for hepatitis C patients with established cirrhosis.
Some functions related to cancer are overrepresented in these
sub-networks, like cell adhesion, positive regulation of DNA
replication, positive regulation of cell proliferation, etc (Sup-
plementary Data S3).
To verify our hypothesis and those identified disease relate sub-
networks. We randomly selected three sub-networks from the
twenty seven progression-related sub-networks annotated as
statistically significant functions and carried out the text mining
from published literature. One sub-network is deregulated from
hepatitis C, another sub-network is generated from cirrhosis data
and the last one signifies the deregulation from BCLC stage 0
HCC. In the sub-network that is deregulated from hepatitis C
(Figure 3A), HLA-DQA1 and DQB1 are associated with
development of cirrhosis, and DQB1 could be risk factors for
the occurrence of HCC [20,21]. COL1A2, a protein in the sub-
network which is deregulated from cirrhosis, is involved in the
development or progression of hepatoma [22]. Moreover, ESR1,
the core protein, which interacts with most nodes in this sub-
network, of the network that is deregulated from BCLC stage 0
HCC, have been shown to be associated with an increased
hepatocellular carcinoma risk [23].
Discussion
The progression-related sub-network deregulated in hepatitis C
infection stage was constructed with four nodes (HLA-DQA1,
HLA-DQB1, HLA-DPA1 and CD74) and interactions among
them (Figure 3A). We proposed that this sub-network is potentially
related to cirrhosis-HCC-risk, considering that those genes are
differentially expressed in hepatitis C stage. It could be seen that
many important functions, including positive regulation of B cell
proliferation, negative regulation of apoptosis, etc., are enriched
significantly (P value,0.01) in this sub-network (Table 1). In this
sub-network, CD74 is the major histocompatibility complex, class
II invariant chain. HLA-DQA1 and HLA-DPA1 belong to the
Figure 3. Sub networks that mentioned in discussion. (A) Sub network that deregulated initially from hepatitis C. (B) One of the sub networks
that deregulated initially from cirrhosis; (C) One of the sub networks that deregulated initially from BCLC stage 0 HCC.
doi:10.1371/journal.pone.0018516.g003
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the HLA class II beta chain paralogues.
The class II molecule is a heterodimer consisting of an alpha
(DPA, DQA) and a beta (DPB, DQB) chain, both anchored in the
membrane. It plays a central role in the immune system by
presenting peptides derived from extracellular proteins. Within the
DP and DQ molecules both the alpha chain and the beta chain
contain the polymorphisms specifying the peptide binding
specificities, resulting in up to 4 different molecules.
DQB1*0201 allele has been confirmed to be closely correlated
with the progression of liver injury in chronic HCV infection [24].
Meanwhile, DQA1*0103 appears to provide protection against
chronic active infection with hepatitis C virus [25]. Moreover,
HLA-DQA1 and DQB1 are associated with development of
cirrhosis, and DQB1 might be a risk factor for the occurrence of
HCC [20,21]. Since full function of major histocompatibility
complex needs both the invariant chain and variant chain, the
PPIs among DQA1, DQB1 and CD74 may participate in the
induction of hepatitis C and the development and progression
from hepatitis C to HCC.
Our network-based view shows that three progression-related
sub-networks appear deregulated initially in cirrhosis stage. One of
the sub-networks is composed of four nodes (VWF, LUM,
COL1A1 and COL1A2) with four interactions among them
(Figure 3B), and it can be considered an HCC-risk related sub-
network. Certain functions, like, cell adhesion, are significantly
enhanced (P value,0.01) in this sub-network (Table 2). Within the
same sub-network, VWF functions as an antihemophilic factor
carrier and a platelet-vessel wall mediator in the blood coagulation
system. LUM is a member of the small leucine-rich proteoglycan
(SLRP) family that includes decorin, biglycan, fibromodulin,
keratocan, epiphycan, and osteoglycin. In these bifunctional
molecules, the protein moiety binds collagen fibrils and the highly
charged hydrophilic glycosaminoglycans regulate interfibrillar
spacings. Lumican is the major keratan sulfate proteoglycan of
the cornea but is also distributed in interstitial collagenous
matrices throughout the body. Lumican may regulate collagen
fibril organization and circumferential growth, corneal transpar-
ency, and epithelial cell migration and tissue repair. COL1A1 is
the pro-alpha1 chains of type I collagen whose triple helix
comprises two alpha1 chains and one alpha2 chain. COL1A2 is
the pro-alpha2 chain of type I collagen whose triple helix
comprises two alpha1 chains and one alpha2 chain. Type I is a
fibril-forming collagen found in most connective tissues and is
abundant in bone, cornea, dermis and tendon.
COL1A1 and COL1A2 are associated with liver fibrogenesis
[26,27]. Moreover, COL1A2 is involved in the development or
progression of hepatoma [22]. VWF mRNA has been shown to be
significantly upregulated in both fibrosis and HCC [28]. In
patients with fulminant hepatic failure and liver cirrhosis,
circulating plasma VWF antigen levels are extremely high
[29,30,31]. Many fibrin thrombi have been found in the hepatic
sinusoids in acute liver failure, suggesting a role for intravascular
coagulation in the pathogenesis of hepatic necrosis [32]. In
cirrhotic liver tissue [33] and even tissue from patients in early
stages of alcoholic liver diseases [34], VWF immunostaining shows
positive cells predominantly at the scar–parenchyma interface,
within the septum, and in the sinusoidal lining. Portal or hepatic
vein thrombosis is often observed in advanced cirrhosis [35,36]
and microthrombi formation has been found in one or multiple
organs in half of autopsied cirrhotics [37]. This hypercoagulable
state in liver diseases may be involved in hepatic parenchymal
extinction, the acceleration of liver fibrosis, and disease progres-
sion. Lumican has diverse biologic roles but has been thought to
be primarily involved in fibrosis of the extracellular matrix through
the binding of collagen fibrils and regulation of their lateral growth
[38,39]. Lumican expression is also increased with progression of
hepatic fibrosis in rats [40]. Decreased sulforylation of lumican
side chains stimulates macrophage adhesion and the cellular
inflammatory response [41,42], suggesting that changes in the
structure of lumican may promote the inflammatory process that
precedes and enhances collagen deposition during the process of
hepatic fibrosis. Taken together, it implies that PPIs among
COL1A1, COL1A2, VWF and LUM may participate in the
induction of cirrhosis and play roles in the progression from
cirrhosis to HCC.
The progression-related sub-networks deregulated from BCLC
stage 0 HCC included 11 sub-networks. The biggest sub-network
in this category was comprised of 34 nodes with 42 PPIs and 2
TRIs (Figure 3C). Many functions are significantly enriched in this
sub-network (Table 3), including induction of apoptosis, cell cycle
arrest, etc. A core protein of this sub-network is ESR1, which
interacts with most nodes in this sub-network. This protein
regulates the expression of FOS, and subsequently FOS regulates
HBA1. HBA1 participate in a smaller sub-network that construct-
ed by four nodes (HBA1, HBB, HBA2, HBG2) with interactions
among them. ESR1 is an estrogen receptor, a ligand-activated
transcription factor composed of several domains important for
hormone binding, DNA binding, and activation of transcription.
FOS can dimerize with proteins of the JUN family, thereby
forming the transcription factor complex AP-1. As such, the FOS
proteins have been implicated as regulators of cell proliferation,
differentiation, and transformation. In some cases, expression of
the FOS gene has also been associated with apoptotic cell death.
The alpha (HBA) and beta (HBB) loci determine the structure of
the 2 types of polypeptide chains in adult hemoglobin, Hb A. The
Table 2. Significant functions (P value,0.01) of the
progression-related sub network deregulated initially from
cirrhosis.
GO ID P value Name
GO:0005783 5.86E-03 endoplasmic reticulum
GO:0007596 4.26E-04 blood coagulation
GO:0047485 5.02E-03 protein N-terminus binding
GO:0033093 1.70E-04 Weibel-Palade body
GO:0019865 1.70E-04 immunoglobulin binding
GO:0030168 6.81E-04 platelet activation
GO:0051087 8.51E-04 chaperone binding
GO:0051260 1.70E-03 protein homooligomerization
GO:0005178 1.11E-03 integrin binding
GO:0005576 7.57E-07 extracellular region
GO:0007599 1.70E-04 Hemostasis
GO:0031012 6.81E-04 extracellular matrix
GO:0043231 0.003232767 intracellular membrane-bounded
organelle
GO:0002020 0.001362122 protease binding
GO:0031589 0.000170341 cell-substrate adhesion
GO:0007155 0.000766365 cell adhesion
GO:0005518 0.000510959 collagen binding
GO:0001948 0.000936609 glycoprotein binding
doi:10.1371/journal.pone.0018516.t002
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GO ID P value Name
GO:0000118 9.14E-08 histone deacetylase complex
GO:0005634 3.22E-07 Nucleus
GO:0005876 7.34E-07 spindle microtubule
GO:0005515 2.34E-06 protein binding
GO:0017053 2.75E-06 transcriptional repressor complex
GO:0003714 5.82E-06 transcription corepressor activity
GO:0004861 8.55E-06 cyclin-dependent protein kinase inhibitor activity
GO:0042326 1.79E-05 negative regulation of phosphorylation
GO:0010553 2.92E-05 negative regulation of gene-specific transcription from RNA polymerase II promoter
GO:0000082 0.000129787 G1/S transition of mitotic cell cycle
GO:0005737 4.66E-04 Cytoplasm
GO:0042826 7.90E-04 histone deacetylase binding
GO:0007050 0.00090131 cell cycle arrest
GO:0006917 9.79E-04 induction of apoptosis
GO:0030308 0.001019554 negative regulation of cell growth
GO:0008285 1.23E-03 negative regulation of cell proliferation
GO:0019901 0.001821703 protein kinase binding
GO:0030332 1.87E-03 cyclin binding
GO:0043697 0.001871365 cell dedifferentiation
GO:0045646 0.001871365 regulation of erythrocyte differentiation
GO:0042063 0.001871365 Gliogenesis
GO:0007517 0.001871365 muscle organ development
GO:0046825 0.001871365 regulation of protein export from nucleus
GO:0005088 0.001871365 Ras guanyl-nucleotide exchange factor activity
GO:0008637 0.001871365 apoptotic mitochondrial changes
GO:0071158 0.001871365 positive regulation of cell cycle arrest
GO:0044428 1.87E-03 nuclear part
GO:0045668 2.81E-03 negative regulation of osteoblast differentiation
GO:0070215 2.81E-03 MDM2 binding
GO:0043517 0.002805763 positive regulation of DNA damage response, signal transduction by p53 class mediator
GO:0010389 0.002805763 regulation of G2/M transition of mitotic cell cycle
GO:0001953 0.002805763 negative regulation of cell-matrix adhesion
GO:0031648 2.81E-03 protein destabilization
GO:0007265 0.003255111 Ras protein signal transduction
GO:0051225 3.74E-03 spindle assembly
GO:0045736 3.74E-03 negative regulation of cyclin-dependent protein kinase activity
GO:0001954 0.003739306 positive regulation of cell-matrix adhesion
GO:0004693 4.67E-03 cyclin-dependent protein kinase activity
GO:0000080 0.004671996 G1 phase of mitotic cell cycle
GO:0032993 0.004671996 protein-DNA complex
GO:0000075 5.60E-03 cell cycle checkpoint
GO:0006338 0.005603832 chromatin remodeling
GO:0006309 0.005603832 DNA fragmentation involved in apoptosis
GO:0050680 0.006534815 negative regulation of epithelial cell proliferation
GO:0046329 0.007464947 negative regulation of JNK cascade
GO:0050821 0.007464947 protein stabilization
GO:0032088 8.39E-03 negative regulation of NF-kappaB transcription factor activity
GO:0016055 0.008394228 Wnt receptor signaling pathway
GO:0006469 0.009322658 negative regulation of protein kinase activity
GO:0051059 9.32E-03 NF-kappaB binding
doi:10.1371/journal.pone.0018516.t003
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and two beta chains. Mutation in beta globin is the cause of sickle
cell anemia. Absence of beta chain causes beta-zero-thalassemia.
Reduced amounts of detectable beta globin causes beta-plus-
thalassemia.
Animal models and human epidemiologic studies have
suggested that estrogens act as tumor promoters and might
induce hepatocarcinogenesis [43,44,45,46]. The estrogens exert
the effects by binding to estrogen receptors (ESR). The genetic
polymorphisms within ESRs could influence the effects of
estrogens, which in turn results in genotype-dependent
differences in risk for hepatocellular carcinoma. Indeed, the
polymorphisms in the 59 end of the ESR a (ESR1) gene have
been shown to be associated with an increased hepatocellular
carcinoma risk, supporting the involvement for the estrogen-
ESR axis in the estrogen-induced hepatocarcinogenesis [23].
The oncogene c-fos (FOS), which is required for quiescent cells
to enter the cell cycle [47], also is up-regulated in HCC [48].
HBV X peptide has been shown to activate the c-fos gene,
which is postulated to contribute to hepatocarcinogenesis [49].
Our result implies that the association between ESR1 and FOS
may participate in the process of HCC initiation and may play
roles in the progression of carcinogenesis from early to
advanced HCC. Moreover, the hemoglobin (Hb A) level may
be deregulated by this association in the progression of
carcinogenesis from early HCC.
Previous studies have indicates that when hepatitis C patients
establishes cirrhosis, the HCC incidence will increase largely.
Cirrhosis is an important stage in the progression from hepatitis
C to HCC. In the cirrhosis-related network, we can recognize
some interesting components and relationships (Figure 4). The
nodes that appeared in cirrhosis-HCC-risk sub-network are
located close to the nodes belonging to HCC-risk sub-networks.
They are connected by CD44. The CD44 is a cell-surface
glycoprotein. The CD74, a protein of cirrhosis-HCC-risky related
sub-network, is also membrane protein and the rest of the sub-
network proteins are located extracellularly. Similarly, the
proteins in HCC-risk related sub-networks are also located in
extracellular region. It could be anticipated that the synergistic
action between deregulated cirrhosis-HCC-risky related sub-
network and HCC-risky related sub-networks could be one of the
reasons for the dramatic increase of HCC incidence when
hepatitis C patients develop cirrhosis. As we mentioned before,
the dysfunction of cirrhosis-HCC-risk related sub-network
emerges from hepatitis C, while the dysfunction of HCC-risk
related sub-networks gets started from cirrhosis. Those relation-
ships and results supported by the experimental evidences imply
that the dysfunction of HCC-risk related sub-networks is under
the influence of the dysfunction of the cirrhosis-HCC-risk related
sub-network.
Although we have identified progression-related sub-networks
for HCV induced hepatocarcinogenesis and recognized some
potential synergistic actions of proteins and genes in the sub-
network, our approach has certain limitations. First, we only use
experimentally confirmed interaction data in our analysis. So some
potential associations among DEGs may be lost. Second, our
analysis depends not only on biological reality but also on
sampling, experimental conditions, and reported results; there
could be other genes and proteins that significantly contribute to
network functions not yet addressed.
In conclusion, we constructed the disease-related biological
networks through the integration of those DEGs, PPIs and TRIs
data for different stages of hepatitis C infected disease, including
liver cancer. By comparison of the disease-related biological
networks between each stage, the dynamic characteristics of the
networks show that they mostly reflect the important features of
the disease development and progression, which provides
important information for us to explore the underlying
mechanisms of the diseases. We identified progression-related
sub-networks in the development and progression through
dynamic biological network analysis and annotated significant
functions of these sub-networks. Text mining results from
published literature confirmed our hypothesis largely in the
examples randomly chosen. It implies that these progression-
related sub-networks, especially the ones which are annotated
with significant functions, can be helpful in the understanding of
molecular mechanism that underlies the progression of HCV
induced hepatocarcinogenesis.
Materials and Methods
Microarray data and DEG
Microarray data was collected from Gene Expression Omnibus
(GEO) database. Two datasets (GSE6764, GSE9843) were used in
this analysis. They contain 10 normal samples, 21 hepatitis
samples, 13 cirrhosis samples, 9 BCLC stage 0 HCC samples, 56
BCLC stage A HCC samples, 7 BCLC stage B HCC samples, 8
BCLC stage C HCC samples. Normal samples, hepatitis samples
and cirrhosis samples were from GSE6764. BCLC staging HCC
samples were from GSE9843. All samples except for normal ones
were HCV infected. Both GSE6764 and GSE9843 were based on
GPL570 platform: [HG-U133_Plus_2] Affymetrix Human Ge-
nome U133 Plus 2.0 Array. And there were no technical replicates
in both of the two datasets. The differentially expressed genes
(DEGs) were collected for further analysis if the expression
alteration between the disease sample and normal controls was
greater than 2 fold. We identified up-regulated DEGs and down-
regulated DEGs for each disease sample.
Detection of deregulated biological network
Protein-protein interactions data and transcriptional regulatory
interactions data came from HCCNet database [16], which was a
HCC network database previously established by our team, The
database contains 37811 experimentally confirmed protein-
protein interactions and 9148 experimentally confirmed transcrip-
tional regulatory interactions. Those data were used to construct
deregulated biological networks of each disease stage. Firstly,
DEGs indentified in each disease sample were mapped to PPI and
TRI data. Then deregulated interactions between DEGs were
identified and used to construct the individual deregulated
biological network. An individual deregulated biological network
is a network constructed by deregulated PPIs and TRIs identified
in one disease sample. When all individual deregulated networks of
a disease were constructed, occurrence frequency of each
deregulated interaction in the disease could be calculated. Rd
represents the occurrence frequency of a deregulated interaction in
a disease. Nd signifies the number of disease samples in which the
interaction is deregulated. Na represents the number of all the
samples of the disease.
Rd~
Nd
Na
ð1Þ
If Rd of an interaction is more than 0.5, it means that this
interaction is deregulated in more than half of the cases of a
disease, the interaction can be regarded as high confidently
deregulated one and the dysfunction value X of the interaction is
defined as 1, otherwise it is defined as 0. In other words, we believe
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disease.
X~
1, Rd§0:5
0, Rdv0:5

ð2Þ
With those indentified deregulated interactions, deregulated
biological network of each disease stag was constructed for further
analysis. Finally, deregulated biological networks in six stages were
established accordingly.
Detection of progression-related biological sub-network
When the progression of the disease advances from hepatitis C
to BCLC stage C HCC, the deregulated biological network
changes correspondingly. Six disease stages were considered in this
progression: Hepatitis C, Cirrhosis, BCLC stage 0 HCC, BCLC
stage A HCC, BCLC stage B HCC, BCLC stage C HCC. Some
interactions are deregulated initially in one stage and keep
dysfunction in the following stages, they may participate in the
development stage of the disease in which they are deregulated
initially and may also play a role in the following progression
Figure 4. Cirrhosis-related network mentioned in discussion. Node color: green, nodes used to be in cirrhosis-HCC-risky sub-network; yellow,
nodes in HCC-risky sub-network; purple, other nodes in cirrhosis-related network. Edge color: red, PPI; green, TRI. Edge direction: undirected, PPI;
directed, TRI, from transcriptional factor to target gene.
doi:10.1371/journal.pone.0018516.g004
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disease stage, the X value of the interaction is 1, otherwise the X
value is 0. So when an interaction is deregulated initially in
hepatitis C and keeps dysfunction in the following disease stage,
the FHe(X) will be 1. In other words, when the value of FHe(X) is
1, the interaction is initially in hepatitis C and keeps dysfunction in
the following disease stage.
FHe(X)~ P
Bc
i~He
Xi ð3Þ
Generally, we defined an indicator function FS(X) as:
FS(X)~ P
s{1
i~He
Xi P
Bc
i~s
Xi ð4Þ
which equals to 1 when an interaction is deregulated initially in
stage S and keeps dysfunction in the following disease stages,
where S[fHe,Ci,B0,Ba,Bb,Bcg. He represents hepatitis C, while
Ci represents cirrhosis. Similarly, B0, Ba, Bb and Bc represent
BCLC stage 0, BCLC stage A, BCLC stage B and BCLC stage C
of HCC, respectively. The order is from He to Bc. So when S is Ci,
S-1 is He. When S is He, we define S-1 is 0 and P
0
i~He
Xi~1.I n
other words, when S is He, the formula can be presented as:
FHe(X)~ P
Bc
i~He
Xi.
Detection of significant functions of sub-networks
Inourpreviouswork,weannotated eachinteraction ofintegrated
biological network with a new Gene Ontology based annotation
method that developed by ourself. Gene Ontology annotation data
of Homo sapiens was downloaded on April 20, 2010. We filtered
annotations which are supported by experiment evidence and used
them in the annotation of interactions. With the annotated
interaction data and hypergeometric distribution method, we
compare each sub-network to the whole biological network and
identified statistical significant functions (p value,0.01) of each sub-
network. Statistical analysis is performed with R.
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